Alnylam Pharmaceuticals Inc (ALNY)vsPalatin Technologies Inc (PTN)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
PTN
Palatin Technologies Inc
$21.00
+5.79%
HEALTHCARE · Cap: $46.82M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 41877% more annual revenue ($3.71B vs $8.85M). ALNY leads profitability with a 8.5% profit margin vs -54.3%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
PTN
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for PTN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Strong operational efficiency at 52.7%
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 51.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : PTN
The strongest argument for PTN centers on Operating Margin.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : PTN
The primary concerns for PTN are PEG Ratio, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while PTN is a turnaround play — different risk/reward profiles.
ALNY carries more volatility with a beta of 0.38 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 32/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Palatin Technologies Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Palatin Technologies, Inc., a specialty biopharmaceutical company, develops targeted receptor-specific therapies for the treatment of various diseases in the United States. The company is headquartered in Cranbury, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?